Introduction
============

Takotsubo cardiomyopathy (TTC), a well-known reversible disease, was first described in 1991.[@b1-cmc-10-2016-117] It is characterized by the transient apical ballooning of the left ventricle (LV) with wall motion abnormalities of the middistal and apical regions and is generally associated with a decreased ejection fraction (EF). Right ventricular (RV) involvement has been described in up to 27% of patients,[@b2-cmc-10-2016-117],[@b3-cmc-10-2016-117] and a spontaneous recovery of the myocardial muscle is usually observed within a few days or weeks.

Patients present initially with symptoms, such as chest pain and dyspnea, which may mimic an acute coronary artery syndrome (ACS), and treatment is begun as per the ACS protocol by admitting to the hospital. Arrhythmias, cardiogenic shock, thromboembolic events, and in worst cases, in-hospital death are the well documented TTC-related complications. The in-hospital mortality rate of TTC is comparable with the mortality rate of ACS.[@b4-cmc-10-2016-117],[@b22-cmc-10-2016-117] A few thromboembolic events in patients with TTC have been described in some case reports[@b5-cmc-10-2016-117]--[@b7-cmc-10-2016-117]; however, there has been no documented systemic review available yet to address this acute scenario.

Materials and Methods
=====================

We retrospectively describe a collection of 114 consecutive patients diagnosed with TTC between January 2003 and September 2015 at our institution. The patients were diagnosed according to the Mayo Clinic Criteria,[@b8-cmc-10-2016-117] which outlines the clinical features associated with TTC.

The first criterion describes the transient wall motion abnormality in the left ventricular mid segments associated with or without apical involvement; regional wall motion abnormalities that extend beyond a single epicardial vascular distribution; and frequently in the event of a stressful trigger. The second criterion outlines the absence of obstructive coronary disease. The third criterion mentions the appearance of new ECG pathologies, which mimic ACS or modest elevations in cardiac troponin levels. The final criterion is the absence of pheochromocytoma and myocarditis in the patient.

The study population underwent a 12-lead ECG, echocardiography, coronary angiography, and in some cases, cardiac magnetic resonance tomography. Most patients were monitored in the intensive care unit for at least 24 hours.

The angiograms, echocardiograms, and ECGs were reviewed by two independent cardiologists who evaluated the diagnosis of TTC. This study was conducted in compliance with the Declaration of Helsinki with regard to investigations in human subjects, and the study protocol was approved by the Ethics Committee of University Medical Centre Mannheim.

In-hospital events, such as life-threatening arrhythmias (ventricular tachycardia, ventricular fibrillation, asystole, and AV-block II type mobitz and complete AV block), cardiac rupture, thromboembolic events, pulmonary congestion with the use of noninvasive positive-pressure ventilation, endotracheal intubation, use of a temporary pacemaker, use of inotropic agents, and in-hospital death, were assessed based on chart review.

The aim of this study was to better understand the predictors, clinical significance, and short-term and long-term outcomes, defined as all cause of death of patients with TTC complicated with an acute thromboembolic event on initial presentation.

Statistics
----------

Data are presented as mean ± SD for continuous variables with a normal distribution, as median (inter-quartile range) for continuous variables with a non-normal distribution, and as frequency (%) for categorical variables. The Kolmogorov--Smirnov test was used to assess normal distribution. Student's *t*-test and the Mann--Whitney *U*-test were used to compare continuous variables with normal and non-normal distributions, respectively. The chi-squared test or Fisher's exact test was used to compare categorical variables. In all analyses, *P* \< 0.05 (two-tailed) was taken to indicate statistical significance.

Results
=======

Clinical features of patients with TTC
--------------------------------------

The mean age of patients with TTC was 67 ± 11 years with female predominance (83%) ([Table 1](#t1-cmc-10-2016-117){ref-type="table"}). Seventy percent of the patients were admitted to the hospital with clinical symptoms of ACS, the most common clinical symptom being chest pain (50.8%) followed by dyspnea (37%). ST-segment elevation in ECG was observed in 34 patients (30%), and inverted T-waves were observed in 102 patients (89.5%). Patient histories revealed emotional and physical stresses in 29% and 56% of the cases, respectively. A mild elevation of cardiac enzymes, such as troponin I and creatine kinase, was confirmed in 95% of the cases for troponin I and in 43% of the cases for creatine kinase. The left ventricular function, measured by transthoracic echocardiography and laevocardiography, was significantly reduced in almost all patients during hospital admission (EF 38.3%). RV involvement was documented in 22.8% of the cases. An apical type TTC was observed in 71.9% (*n* = 82) of the patients, whereas midventricular type and reversed type were diagnosed in *n* = 30, 26.3% and *n* = 2, 1.7% respectively.

The most frequent complications associated with TTC were life-threatening arrhythmias (11.4%), pulmonary congestion with need for invasive respiratory support (20%), thromboembolic events (12.2%), cardiogenic shock (19.2%), and in-hospital death (7.8%).

Clinical findings of patients with thromboembolism
--------------------------------------------------

The thromboembolic events occurred exclusively in the arterial system and patients suffering from this complication were predominantly (92.8%) postmenopausal females with a mean age of 67 ± 13.1 years. Also, initial ECGs revealed ST-segment elevation in 57.1% of the patients.

A physical trigger was more than often responsible for the chain of events as compared to an emotional cause (78.5% versus 14.2%). The apical variant of TTC was identified in 11 (78.5%) patients, whereas the midventricular variant of TTC was identified in 3 patients (21.4%). RV involvement was diagnosed in six patients (42.8%). Due to worsening circulatory status, catecholamine therapy was initiated in four cases, whereas invasive respiratory support was required in five patients due to impending cardiogenic shock. One patient received extracorporeal membrane oxygenation therapy.

The database documented a single female patient experiencing a recurrent TTC. Interestingly, this patient showed a biventricular form of TTC the second time around compared to a left ventricular TTC in the past. The in-hospital death of patients associated with TTC complicated by a thromboembolic event was calculated to be 14%. The cause of death was attributed to an acute cardiac failure (respiratory distress triggered by cardiogenic shock and pulseless electrical activity).

The distribution of the thromboemboli and its presenting location are indicated in [Table 2](#t2-cmc-10-2016-117){ref-type="table"}. Only one patient with previously diagnosed atrial fibrillation presented with a thrombus in the LV. Newly diagnosed atrial fibrillation at index event of TTC was similar in both groups (14.2% versus 4%; *P* \> 0.1).

In this study, 11 patients with proven thromboembolic events were started on an anticoagulant therapy with either warfarin or heparin. Three patients (stroke and occlusion of retinal artery) were treated with aspirin. In one patient, a thromboendarterectomy was performed.

Patients with TTC presenting with thromboembolic events were compared with patients with TTC who were not affected by such complications, and this revealed a similar predominance of females suffering from physical stress (78.5% versus 53%; *P* = 0.08). Also, no significant difference between the two groups could be elucidated when clinical symptoms, cardiac enzyme levels, creatinine levels, and hemoglobin levels were compared. However, patients who experienced thromboembolic events did show higher CRP levels (118 ± 145 mg/dL versus 40 ± 58 mg/L; *P* = 0.02). Furthermore, ST-segment elevation was more frequent in patient with thromboembolic events (57.1% versus 26%; *P* = 0.02). The frequency of cardiovascular risk factors, such as obesity, arterial hypertension, diabetes mellitus, and history of smoking, was similar in both groups. The EF and the *takotsubo variant* were also similar in both groups.

Pertaining to RV involvement, this was documented more often in patients who had experienced a thromboembolic event (42.8% versus 19%; *P* = 0.05). Additionally, the incidence of other TTC-related complications, such as cardiogenic shock, respiratory distress, in-hospital death, and life-threatening arrhythmias (ventricular tachycardia, ventricular fibrillation, asystole, and AV-block II type mobitz and complete AV block), were similar in both groups.

Long-term prognosis
-------------------

Kaplan--Meier analysis indicated that short-term mortality rate (30 days) was similar in both groups. But nevertheless, long-term mortality rate was significantly higher in the thromboembolic group ([Fig. 1](#f1-cmc-10-2016-117){ref-type="fig"}).

Discussion
==========

TTC occurs predominantly in postmenopausal women.[@b9-cmc-10-2016-117]--[@b11-cmc-10-2016-117],[@b13-cmc-10-2016-117] and the disease is usually provoked by emotional or physical stress.[@b2-cmc-10-2016-117]--[@b6-cmc-10-2016-117] An enhanced sympathetic activity with an elevation of catecholamine levels has been documented in these patients.[@b14-cmc-10-2016-117] Furthermore, coronary vasospasm and widespread coronary microvascular dysfunction[@b10-cmc-10-2016-117],[@b15-cmc-10-2016-117] might be a contributing factor in the pathophysiologic mechanism of TTC. Nevertheless, a defining explanation to its underlying pathogenesis remains unresolved.

In this study, we first investigate the risk of acute thromboembolism in 114 patients diagnosed with TTC. To date, the incidence and clinical significance of acute (in-hospital) thromboembolic events in TCC have not been well established. Our literature search revealed single case report or cohort of maximum 21 patients.[@b16-cmc-10-2016-117]--[@b19-cmc-10-2016-117],[@b23-cmc-10-2016-117] A 1%--4.2% in-hospital mortality rate of patients with TTC has also been reported.[@b4-cmc-10-2016-117],[@b20-cmc-10-2016-117],[@b21-cmc-10-2016-117] Interestingly, further TTC-related complications, such as congestive heart failure, cardiogenic shock, respiratory distress, and lethal arrhythmias, have been well presented.[@b5-cmc-10-2016-117],[@b22-cmc-10-2016-117] In this work, the frequency of acute thromboembolic events in patients with TTC was 12.2%, and this was predominantly documented in postmenopausal women. This might be due to the higher incidence of TTC in females and is in accordance with the further investigations of the TTC cohort of 21 patients mentioned earlier.[@b19-cmc-10-2016-117]

In 42.8% of patients with thromboembolic events, there was a thrombus diagnosed in the left and/or right ventricle. A meta-analysis of Gregorio et al reported thrombi in the LV in 2.5% of patients with TTC.[@b5-cmc-10-2016-117] Our work demonstrates a risk of approximately 5.2%. The development of thrombus or emboli in the right ventricle in patients with TTC has not yet been reported. However, in our study, a single patient was diagnosed with thrombi in both ventricles. This patient was then classified as presenting with a biventricular form of TTC.

Ventricular thrombus can occur in the setting of ventricular dysfunction, especially in the acute stage postmyocardial infarction.[@b24-cmc-10-2016-117],[@b25-cmc-10-2016-117] In patients with noncompaction cardiomyopathy and dilated cardiomyopathy, the coincidental development of thrombi has been also reported.[@b26-cmc-10-2016-117],[@b27-cmc-10-2016-117] Left ventricular thrombus may be associated with antiphospholipid antibody syndrome, hypereosinophilic syndrome, and other autoimmune disorders, such as Adamantiadis-Behcet's disease and lupus erythematosus.[@b28-cmc-10-2016-117]--[@b31-cmc-10-2016-117] In TTC, an acute ventricular embolism is presumably explained due to the low blood flow in the ventricle. In addition, it has been hypothesized that the coagulation cascade plays a role influencing the underlying mechanism of thromboembolic development.[@b32-cmc-10-2016-117]

In this study, we also demonstrate that acute cerebrovascular events occurred with a frequency of approximately 2.6%. However, data from existing literature revealed a higher rate of acute cerebrovascular events in TTC of up to 9%.[@b19-cmc-10-2016-117] In contrast, previous randomized controlled trials revealed that only 4.6% of patients with ACS experienced stroke.[@b33-cmc-10-2016-117]

In this study, the incidence of thromboembolism in more than one organ was observed in 14.2% of the patients. Interestingly, the occlusion of retinal artery due to embolism in patients with TTC has not been reported yet.

In our thromboembolism cohort, anticoagulation treatment in most cases was initiated with heparin or warfarin (78%). Although anticoagulation is generally recommended, the type and duration of anticoagulant treatment remain unresolved.

Our report also revealed that patients with TTC who experience thromboembolic events have higher CRP levels. This indicates a potential pathogenic role of inflammation in the development of thromboembolic events. Similar findings have been reported in patients with thromboembolic events in patients with ACS.[@b34-cmc-10-2016-117]

Furthermore, we demonstrated that RV involvement assessed by transthoracic echocardiography correlates with the thromboembolic events in TTC. Although the mildly reduced left EF was similar in both groups, patients with thromboembolic events presented a significant ST-segment elevation. It has been reported that a thromboembolic event, such as pulmonary artery embolism, is associated with ST-segment elevation.

Conclusions
===========

Our results indicate that the prevalence of acute thromboembolic events is higher than expected in TTC and is associated with a high long-term mortality rate. This complication can occur in every organ, irrespective to the presence or absence of a ventricular thrombus. Anticoagulation therapy might be the sole therapy for all high-risk TTC patients and should be prescribed during the in-hospital phase to prevent such events. We recommend further studies to evaluate the occurrence and prevalence of out of hospital thromboembolic events.
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###### 

Baseline characteristics of 114 patients presenting with Takotsubo cardiomyopathy.

  VARIABLES                                     ALL PATIENTS (n = 114)   TTC WITHOUT TE EVENTS (n = 100)   TTC WITH TE EVENTS (n = 14)   *P* VALUE[\*](#tfn1-cmc-10-2016-117){ref-type="table-fn"}
  --------------------------------------------- ------------------------ --------------------------------- ----------------------------- -----------------------------------------------------------
  **Demographics**                                                                                                                       
  Age, mean ± SD                                67 ± 11                  67.1 ± 11                         67 ± 13.1                     0.956
  Female, n (%)                                 95 (83)                  82 (82)                           13 (92.8)                     0.313
  **Symptoms, n (%)**                                                                                                                    
  Chest pain                                    58 (50.8)                54 (54)                           4 (28.5)                      **0.077**
  Dyspnea                                       43 (37)                  37 (37)                           6 (42.8)                      0.677
  **ECG Data, n (%)**                                                                                                                    
  ST-segment elevation                          34 (30)                  26 (26)                           8 (57.1)                      **0.018**
  Inverted T-waves                              102 (89.4)               89 (89)                           13 (92.8)                     0.459
  QTc (ms), mean ± SD                           474 ± 69                 478.5 ± 55                        483 ± 24                      0.634
  **Stress factor, n (%)**                                                                                                               
  Emotional sress                               30 (29)                  28 (28)                           2 (14.2)                      0.280
  Physical stress                               64 (56)                  53 (53)                           11 (78.5)                     **0.073**
  None                                          25 (22)                  23 (23)                           2 (14.2)                      0.466
  **Laboratory values, mean** ± **SD**                                                                                                   
  Troponin I (µg/L)                             3.3 ± 5                  3.3 ± 5                           4.6 ± 6.6                     0.558
  Creatine phosphatkinase (U/L)                 674 ± 2773               680 ± 2786                        330 ± 307                     0.521
  C-Reactive protein (mg/l)                     38.5 ± 57.9              40 ± 58                           118 ± 145                     **0.021**
  **Echocardiography data**                                                                                                              
  LV EF% ± SD                                   38.3 ± 9.4               38 ± 9                            38.6 ± 11.8                   0.918
  Right ventricular involvement, n (%)          26 (22.8)                20 (20)                           6 (42.8)                      **0.056**
  Apical type                                   82 (71.9)                71 (71)                           11 (78.5)                     0.677
  Midventricular type                           30 (26.3)                27 (27)                           3 (21.4)                      0.677
  Reversed type                                 2 (1.7)                  2 (2)                             0 (0)                         1
  **Medical history and risk factors, n (%)**                                                                                            
  Smoking                                       36 (31)                  33 (33)                           3 (21)                        0.388
  Atrial fibrillation                           21 (18.4)                17 (17)                           4 (28.5)                      0.301
  Obesity (BMI \>25 kg/m^2^)                    31 (27.2)                27 (27)                           4 (28.5)                      1
  Arterial hypertension                         66 (58)                  58 (58)                           8 (57)                        0.956
  COPD                                          22 (19.2)                20 (20)                           2 (14.2)                      0.618
  **Complications, n (%)**                                                                                                               
  Life-threatening arrhythmias                  13 (11.4)                10 (10)                           3 (21)                        0.199
  Invasive respiratory support                  23 (20)                  20 (20)                           3 (21)                        0.794
  Recurrence                                    6 (5)                    5 (5)                             1 (7)                         0.746
  Cardiogenic shock                             22 (19.2)                18 (18)                           4(11)                         0.466
  In-hospital death                             9 (7.8)                  7 (7)                             2 (14)                        0.304

**Note:**

*P* values for the comparison between TE group and non-TE group.

**Abbreviations:** TE, Thromboembolic; LV, Left ventricular; EF, Ejection fraction.

###### 

Clinical findings of patients with acute TE events.

  CHARACTERISTIC        CASE 1            CASE 2                    CASE 3           CASE 4          CASE 5      CASE 6     CASE 7           CASE 8     CASE 9                      CASE 10            CASE 11           CASE 12           CASE 13    CASE 14
  --------------------- ----------------- ------------------------- ---------------- --------------- ----------- ---------- ---------------- ---------- --------------------------- ------------------ ----------------- ----------------- ---------- -----------------
  Location              Cerebrovascular   Cerebrovascular, spleen   Thoracic aorta   Biventricular   LV          LV         Retinal artery   LV         Ramus marginalis sinister   Pulmonary artery   Left kidney, LV   Cerebrovascular   LV         Brachial artery
  Age                   79                81                        81               70              68          53         64               69         76                          53                 68                83                57         55
  Sex                   Female            Female                    Female           Female          Female      Female     Female           Female     Female                      Female             Female            Female            Male       Female
  Chest pain            0                 0                         \+               0               0           0          0                0          \+                          \+                 0                 0                 \+         0
  Dyspnea               0                 \+                        0                \+              0           \+         0                \+         0                           \+                 \+                0                 \+         0
  Stress                Physical          Physical                  Emotional        Physical        Emotional   Physical   Physical         Physical   Physical                    Emotional          Physical          Physical          Physical   
  CK (U/L)              760               117                       143              423             48          389        182              114        939                         856                60                323               118        89
  TNI (µg/L)            24                1.25                      1.5              0.9             0.13        7.9        3.1              1.84       0.73                        12                 0.3               4.3               0.05       0.124
  ST elevation          \+                0                         \+               0               \+          \+         0                0          \+                          \+                 0                 \+                \+         0
  Inverted T waves      \+                \+                        0                \+              0           0          \+               \+         0                           0                  \+                \+                0          \+
  Pattern               Apical            Apical                    Apical           Apical          Apical      Apical     Apical           MV         Apical                      Apical             MV                Apical            MV         Apical
  EF                    30%               60%                       40%              30%             38%         43%        40%              26%        40%                         60%                30%               47%               25%        55%
  RV-involvement        \+                \+                        \+               \+              0           0          0                \+         0                           \+                 0                 0                 0          0
  Hypertension          \+                \+                        \+               0               \+          0          \+               0          \+                          0                  0                 \+                \+         0
  Diabetes mellitus     0                 0                         0                0               0           0          0                0          0                           \+                 0                 0                 0          0
  COPD                  0                 0                         0                0               0           \+         0                0          0                           \+                 0                 0                 \+         0
  Arrhythmias           0                 0                         0                0               0           0          0                0          VT                          0                  0                 0                 Asystole   VF
  Respiratory support   0                 \+                        0                0               0           \+         0                0          0                           0                  0                 0                 \+         0
  Shock                 \+                \+                        0                0               0           \+         0                0          0                           0                  0                 0                 \+         
  In-hospital death     \+                0                         0                0               0           0          0                0          0                           0                  0                 0                 \+         0
  ECMO                  0                 0                         0                0               0           0          0                0          0                           0                  0                 0                 \+         0
  Recurrence            0                 0                         \+               0               0           0          0                0          0                           0                  0                 0                 0          0
  Tumor                 0                 Colon                     0                0               0           0          0                Rectum     0                           0                  0                 0                 0          Colon

**Notes:** + for positive, (0) for negative,

**Abbreviations:** TE, Thromboembolic; TNI, Troponin I; CK, Creatine Kinase; EF, Ejection fraction; LV, Left ventricular; RV, Right ventricular; MV, Midventricular; VT, Ventricular tachycardia; VF, Ventricular fibrillation; ECMO, Extracorporeal membrane oxygenation; COPD, Chronic obstructive pulmonary disease.
